Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial showed adding the investigational drug itacitinib to standard care for 'half-matched' stem cell transplantation may reduce rates of the disease, in which the donor's stem cells attack the patient's healthy tissues.
